ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 63

TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis

Emily Wu1, Richard Bell2, Edward Schwarz3 and Homaira Rahimi4, 1Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Orthopedeatrics, University of Rochester, Rochester, NY, 4Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Animal models, anti-TNF therapy, Computed tomography (CT), flow cytometry, interstitial lung disease and rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Animal Models Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a significant contributor to rheumatoid arthritis (RA) mortality, yet its pathogenesis remains enigmatic. One theory posits that initial inflammatory RA-ILD pathology occurs secondary to systemic inflammation, prior to transitioning to irreversible fibrotic lung disease. This idea is supported by the TNF-transgenic (TNF-Tg) mouse model of RA, which manifests a purely inflammatory pulmonary pathology of interstitial infiltrate, perivascular inflammation, vascular occlusion, and follicle formation. While anti-TNF agents are largely effective for arthritis, some reports have found them to be ineffective, and possibly detrimental, to patients with RA-ILD. Here, we tested the hypothesis that pre-fibrotic inflammatory ILD is reversible by treating established ILD in TNF-Tg mice.

Methods: TNF-Tg mice underwent in vivo micro-computed tomography (µCT) to establish baseline ILD.  Once they achieved a minimum lung tissue volume of 400mm3, mice (n=6) were randomized to 6-weeks of treatment with anti-TNF or Placebo (10mg/kg/wk i.p.). Body weight, grip strength, and knee ultrasound were measured bi-weekly. Terminal outcomes included lung µCT, histology, and flow cytometry.

Results: Anti-TNF treated mice recovered their body weight, grip strength and had resolution of their arthritis. Further, they demonstrated a dramatic yet incomplete amelioration of lung pathology. Total lung tissue volume was significantly reduced vs. placebo (302.25 +/- 38.40mm3 vs. 471.53 +/- 27.13mm3; p<0.0001) (Fig. 1). Histologic analysis corroborated this finding, with marked decreases in interstitial infiltrate, perivascular inflammation, and vascular occlusion in anti-TNF treated lungs. In contrast, prominent follicle-like structures remained (Fig. 2A-C). Flow cytometry identified a novel CD11bint/CD11c– population, which declined with a concomitant increase in a CD11bhi/CD11chi cDC2-like population in placebo treated lungs, and reverted to WT in the anti-TNF treated lungs (Fig. 2D-F).

Conclusion: Our results demonstrate that a purely inflammatory RA-ILD is largely resolved with anti-TNF therapy, supporting the hypothesis that the inflammatory phase of ILD is potentially reversible. Interestingly, the follicle-like structures in the pulmonary tissue were not cleared by anti-TNF therapy, and a novel cell population was identified in TNF-Tg mice lungs that was no longer present after anti-TNF therapy. Further research is needed to investigate the role of the follicle-like structures and to characterize this novel cell population.

 


Disclosure: E. Wu, None; R. Bell, None; E. Schwarz, None; H. Rahimi, None.

To cite this abstract in AMA style:

Wu E, Bell R, Schwarz E, Rahimi H. TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/tnf-%ce%b1-blockade-incompletely-reverses-inflammatory-pulmonary-pathology-in-the-tnf-transgenic-mouse-model-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tnf-%ce%b1-blockade-incompletely-reverses-inflammatory-pulmonary-pathology-in-the-tnf-transgenic-mouse-model-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology